RPG Life Sciences Acquires Raghava Life's API Business for ₹135 Crore
RPG Life Sciences Ltd · Press Release · 03 Sept 2026, 3:53 am
RPG Life Sciences Acquires Raghava Life's API Business for ₹135 Crore On 2nd Sep'26, RPG Life Sciences announced its subsidiary RPGAP will acquire Raghava Life Sciences’ API business for up to ₹135 crore via a slump sale. The deal adds an EU-GMP approved Hyderabad facility with 300 KL capacity, 22 commercialized APIs, and 7 pipeline assets. Following the Actis Generics buyout, this transaction accelerates RPGAP's buy-and-build strategy to bolster its integrated API scale, unlocking backward integration and cost synergies. The acquisition will be funded entirely through RPGAP’s recent equity raise.
Original exchange filing (PDF)
More announcements from RPG Life Sciences Ltd
- Earning call Transcript · 05 Nov 2026
- Audio Recording of Q2FY27 Results Earnings Call held on October 30, 2026 · 31 Oct 2026
- Investor Presentation · 30 Oct 2026
- Amendment to Policy on Related Party Transactions · 30 Oct 2026
- Press Release · 30 Oct 2026
- Outcome of Board Meeting held on October 29, 2026. · 30 Oct 2026
- Financial Result for the quarter ended September 30, 2026 · 30 Oct 2026
- Outcome of Board Meeting · 30 Oct 2026
